We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $318M
This Fund
S&P 500
This Quarter Est. Return
+21.73%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$318M
AUM Growth
+$170M
Cap. Flow
+$133M
Cap. Flow %
41.89%
Top 10 Hldgs %
51.26%
Holding
144
New
59
Increased
36
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
IPSC icon
Century Therapeutics
IPSC
+$6.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.04M
3
PCVX icon
Vaxcyte
PCVX
+$4.51M
4
TNGX icon
Tango Therapeutics
TNGX
+$3.99M
5
TYRA icon
Tyra Biosciences
TYRA
+$3.76M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$81.6M
2
TERN
Terns Pharmaceuticals
TERN
+$5.27M
3
EXEL icon
Exelixis
EXEL
+$3.01M
4
COGT icon
Cogent Biosciences
COGT
+$2.39M
5
BLTE
Belite Bio
BLTE
+$1.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
26
Relay Therapeutics
RLAY
$4.43B
$2.56M 0.81%
257,738
+184,738
+253% +$1.65M
AXSM icon
27
Axsome Therapeutics
AXSM
$11.4B
$2.38M 0.75%
14,055
+1,100
+8% +$190K
DFTX
28
Definium Therapeutics
DFTX
$5.96B
$1.89M 0.59%
+99,887
New +$1.7M
MLYS icon
29
Mineralys Therapeutics
MLYS
$2.37B
$1.88M 0.59%
69,571
+27,546
+66% +$808K
MDGL icon
30
Madrigal Pharmaceuticals
MDGL
$12.3B
$1.78M 0.56%
3,393
+1,533
+82% +$732K
CTMX icon
31
CytomX Therapeutics
CTMX
$741M
$1.75M 0.55%
371,398
+322,500
+660% +$1.64M
LONA
32
LeonaBio Inc
LONA
$74.1M
$1.69M 0.53%
164,676
+36,725
+29% +$239K
SVRA icon
33
Savara
SVRA
$1.12B
$1.61M 0.51%
295,688
+232,926
+371% +$1.3M
CATX icon
34
Perspective Therapeutics
CATX
$363M
$1.58M 0.5%
+379,082
New +$1.6M
ASMB icon
35
Assembly Biosciences
ASMB
$585M
$1.56M 0.49%
56,147
-17,615
-24% -$502K
NERV icon
36
Minerva Neurosciences
NERV
$186M
$1.5M 0.47%
+248,476
New +$1.43M
ZLAB icon
37
Zai Lab
ZLAB
$2.91B
$1.46M 0.46%
+77,858
New +$1.44M
TARS icon
38
Tarsus Pharmaceuticals
TARS
$3.02B
$1.39M 0.44%
19,800
+15,300
+340% +$1.07M
CRVS icon
39
Corvus Pharmaceuticals
CRVS
$1.28B
$1.21M 0.38%
+82,890
New +$1.32M
AVBP icon
40
ArriVent BioPharma
AVBP
$1.39B
$1.16M 0.36%
+50,252
New +$1.13M
LRMR icon
41
Larimar Therapeutics
LRMR
$449M
$1.15M 0.36%
+256,585
New +$1.03M
KRYS icon
42
Krystal Biotech
KRYS
$9.82B
$1.11M 0.35%
4,316
+316
+8% +$84.1K
IVA
43
Inventiva
IVA
$1.1B
$1.11M 0.35%
+200,141
New +$1.22M
LPCN icon
44
Lipocine
LPCN
$17.2M
$998K 0.31%
+124,942
New +$1.09M
SYRE icon
45
Spyre Therapeutics
SYRE
$9.05B
$993K 0.31%
+19,690
New +$742K
BCRX icon
46
BioCryst Pharmaceuticals
BCRX
$2.57B
$976K 0.31%
+102,493
New +$796K
XNCR icon
47
Xencor
XNCR
$1.69B
$965K 0.3%
80,000
-29,554
-27% -$367K
CLDX icon
48
Celldex Therapeutics
CLDX
$3.47B
$929K 0.29%
+29,300
New +$799K
REPL icon
49
Replimune Group
REPL
$1.44B
$921K 0.29%
+120,400
New +$920K
MAZE
50
Maze Therapeutics
MAZE
$1.52B
$917K 0.29%
+30,707
New +$1.36M
1
2
3 4 5

Similar funds

SA
SAM Advisors Oakhurst, California $319M AUM 17.08% 1-Year Est. Return
KI
Keewaydin Investments Southampton, New York $317M AUM
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
FNWM
Financial Network Wealth Management Draper, Utah $316M AUM
MJFG
Mars Jewett Financial Group Bellevue, Washington $316M AUM
KC
KHIS Custodian Dallas, Texas $316M AUM
EC
Edenbrook Capital Mt. Kisco, New York $321M AUM 79.21% 1-Year Est. Return
WA
Waterford Advisors Orchard Park, New York $315M AUM 15.21% 1-Year Est. Return

Seven Fleet Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Seven Fleet Capital Management held 144 positions worth $318M, up 115% from $148M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Seven Fleet Capital Management deployed $133M of net new capital in Q1 2026, opening 59 new positions and adding to 36 existing holdings. Its largest new stake was Century Therapeutics: 2,947,826 shares worth $6.66M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was CG Oncology, an estimated $81.6M trimmed.

  • Seven Fleet Capital Management's largest Q1 2026 buy was Century Therapeutics: 2,947,826 shares worth $6.66M.
  • Seven Fleet Capital Management added most to Agios Pharmaceuticals in Q1 2026, an estimated $5.04M increase.
  • Seven Fleet Capital Management's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $81.6M.
  • Seven Fleet Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $5.27M.
  • Seven Fleet Capital Management's ten largest holdings make up 51% of its $318M portfolio in Q1 2026.
  • Seven Fleet Capital Management opened 59 new positions and closed 29 in Q1 2026.
  • Seven Fleet Capital Management's portfolio value rose 115% quarter-over-quarter to $318M.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.